Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38535 | 0.85 | SLC7A5 (0.55) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL19667341 | 0.85 | SLC7A5 (0.55) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL2703289 | 0.85 | SLC7A5 (0.55) | SLC7A5ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL10477485 | 0.83 | SLC7A5 (0.53) | SLC7A5ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL10477486 | 0.83 | SLC7A5 (0.53) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL21338866 | 0.81 | SCN4A (0.41) | OPRK1OPRM1OPRD1 | |
| SCHEMBL21096393 | 0.81 | OPRK1 (0.38) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL15966897 | 0.81 | SLC7A5 (0.71) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL16261564 | 0.81 | SLC7A5 (0.40) | SLC7A5XIAPOPRK1OPRM1OPRD1 | |
| SCHEMBL19336449 | 0.81 | SLC7A5 (0.40) | SLC7A5XIAPOPRK1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795196-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230146515-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230146515-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-11273149-B2 | Compositions and methods for the treatment of amyotrophic lateral sclerosis, Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, and multiple system atrophy | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20210023062-A1 | Compositions and Methods for the Treatment of Amyotrophic Lateral Sclerosis, Parkinson's Disease, Parkinson's Disease with Dementia, Dementia with Lewy Bodies, and Multiple System Atrophy | STEALTH BIOTHERAPEUTICS INC. | 2021-01-28 | — | — | US | disclosed |
| US-20210002231-A1 | HYBRID MU OPIOID RECEPTOR AND NEUROPEPTIDE FF RECEPTOR BINDING MOLECULES, THEIR METHODS OF PREPARATION AND APPLICATIONS IN THERAPEUTIC TREATMENT | UNIVERSITÉ DE STRASBOURG (FR) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227499-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | PITRM1, NME4, PDF | SLC7A5 1530/4885ALPI 1590/4885PKM 637/4885 |
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | ARG2, NLN, OAT | SLC7A5 392/4885ALPI 4214/4885PKM 545/4885 |
| US-11795196-B2 | Mitochondria-targeting peptides | HSPE1, TFAM, TNNI3 | SLC7A5 2417/4885ALPI 3397/4885PKM 1318/4885 |
| US-11273149-B2 | Compositions and methods for the treatment of amyotrophic lateral sclerosis, Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, and multiple system atrophy | NLN, TARDBP, PARK7 | SLC7A5 1728/4885ALPI 4275/4885PKM 534/4885 |
| US-20210023062-A1 | Compositions and Methods for the Treatment of Amyotrophic Lateral Sclerosis, Parkinson's Disease, Parkinson's Disease with Dementia, Dementia with Lewy Bodies, and Multiple System Atrophy | NLN, TARDBP, PARK7 | SLC7A5 1728/4885ALPI 4275/4885PKM 534/4885 |
| US-20210002231-A1 | HYBRID MU OPIOID RECEPTOR AND NEUROPEPTIDE FF RECEPTOR BINDING MOLECULES, THEIR METHODS OF PREPARATION AND APPLICATIONS IN THERAPEUTIC TREATMENT | OPRL1, OPRM1, NPFFR1 | SLC7A5 2923/4885ALPI 4376/4885PKM 2893/4885 |
| US-20230146515-A1 | MITOCHONDRIA-TARGETING PEPTIDES | HSPE1, TFAM, TNNI3 | SLC7A5 2417/4885ALPI 3397/4885PKM 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.